Literature DB >> 18221165

Medication assisted treatment of drug abuse and dependence: global availability and utilization.

Thomas F Kresina1.   

Abstract

Clinical trials and clinical studies, using patented drugs and drugs off patent, provide data that impact the best treatment practices for substance abuse and dependence. In the United States, medications have been approved for use in the treatment of both alcohol and opioid dependence. Medications are used in the detoxification from drug abuse and dependence in the symptomatic relief of withdrawal. For long term treatment or medical maintenance treatment, medications eliminate the physiological effects of drug use by blocking drug-receptor binding in the brain. Therefore, patented drugs showing interactions with neurotransmitters in the brain, are attractive candidates for treatment efficacy trials. An effective long term treatment paradigm for reducing drug dependence is the combinatorial use of medications that block the effects of drug use with behavior change counseling and psychotherapy. Medications used for the long term treatment of opioid dependence are methadone, buprenorphine, and naltrexone. Pharmacotherapies used in the treatment of alcohol dependence include acamprosate, antabuse and naltrexone. A reliable indicator for successful treatment of drug dependence is time in treatment. Patients remain in long term treatment when they perceive that their health care environment is supportive and non-stigmatizing and with a good patient-provider relationship where their needs are identified and met. Additional medications are needed for individual comprehensive substance abuse treatment plans, particularly for individuals who abuse stimulants. Patented drugs remain an important source of candidate pharmacotherapies comprising medication assistant treatment, part of a comprehensive treatment plan for drug dependence that addresses the medical, social, and psychological needs of the patient. Adapting this drug treatment paradigm globally requires identifying and testing new drug candidates while building and changing programs to patient centered treatment programs that promote access to care and treatment and integrate medical, psychological, and social services.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18221165     DOI: 10.2174/157489107779561652

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  4 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.

Authors:  Lauren E Cipriano; Gregory S Zaric; Mark Holodniy; Eran Bendavid; Douglas K Owens; Margaret L Brandeau
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 3.  Use of the evidence base in substance abuse treatment programs for American Indians and Alaska Natives: pursuing quality in the crucible of practice and policy.

Authors:  Douglas K Novins; Gregory A Aarons; Sarah G Conti; Dennis Dahlke; Raymond Daw; Alexandra Fickenscher; Candace Fleming; Craig Love; Kathleen Masis; Paul Spicer
Journal:  Implement Sci       Date:  2011-06-16       Impact factor: 7.327

4.  Socioeconomic characteristics of alcohol and other substance users, seeking treatment in Sikkim, North East India.

Authors:  Sunil Kumar Pandey; Debranjan Datta; Sanjiba Dutta; Yogesh Verma; Amit Chakrabarti
Journal:  J Pharm Bioallied Sci       Date:  2015 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.